Clinical Case · Kasuistik

Ipsilateral Breast Carcinoma Following Treatment for Primary Breast Lymphoma
D.B. Geffen^a; E. Cagnano^b; M. Tokar^a; S. Ariad^a; M. Koretz^c

^aDepartment of Oncology, ^bInstitute of Pathology, ^cDepartment of Surgery “A” and the Eshkol Breast Health Center, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel

Onkologie 2007;30:134-136
(DOI: 10.1159/000099143)

  Summary

Background: The breast is an unusual site for primary non-Hodgkin’s lymphoma. Carcinoma in the same breast after treatment for lymphoma poses therapeutic challenges, but there is only 1 case report in Japanese, which describes this occurrence. Patient and Methods: A 59-year-old woman was diagnosed with infiltrating ductal carcinoma of the breast after receiving doxorubicinand vincristine-based chemotherapy for ipsilateral primary large cell breast lymphoma. The cancer was of high grade histology, with immunohistochemistry staining 3+ positive for HER2/neu. Results: After lumpectomy and sentinel node biopsy, adjuvant paclitaxel without anthracyclines was given but had to be stopped early because of neurotoxicity. Radiotherapy to the breast was administered, and a 1-year course of trastuzumab was planned. Conclusion: Breast cancer can occur after breast lymphoma. For primary breast lymphoma, cumulative doses of cardiotoxic and neurotoxic drugs should be limited to 3-4 cycles of chemotherapy, using treatment protocols for stage I-II large cell lymphoma. Consolidation radiotherapy should be considered at a dose curative for microscopic breast cancer.

Copyright © 2007 S. Karger GmbH, Freiburg